@article {Rustin692, author = {Rudolph B. Rustin and David P. Vogt and Ronald M. Bukowski and Kirk V. Shepard}, title = {Hepatic artery infusion chemotherapy for colorectal liver metastases}, volume = {57}, number = {8}, pages = {692--696}, year = {1990}, publisher = {Cleveland Clinic Journal of Medicine}, abstract = {Twenty-two patients with hepatic colorectal metastases had Infusaid pumps implanted for hepatic artery infusion chemotherapy, or HAIC. Prior to pump placement, 19 of the 22 patients received percutaneous HAIC with 5-fluorouracil and citrovorum factor. Floxuridine, 0.2 mg/kg/d, was administered via the Infusaid pump and was alternated with saline solution every 2 weeks. HAIC responsiveness was defined as a 50\% or greater reduction in the sum of all diameters of measured lesions on computerized tomography scans and no evidence of extra-hepatic tumor. Nine patients (41\%) had a favorable response to HAIC; four (18\%) had a partial response to percutaneous HAIC and five (23\%) were considered pump responders. All responders had pretreatment liver replacement of less than 50\%. The mean survival after pump placement was 13.6 months for responders and 11.1 months for non-responders. Although there were no operative deaths, the morbidity rate was 36\%, and 31\% of patients manifested significant chemotherapy toxicity. While toxicity is not insignificant and there is no survival benefit, the Infusaid pump is a reliable drug delivery system for HAIC, and may result in regression of colorectal liver metastases in patients with less than 50\% hepatic replacement.}, issn = {0891-1150}, URL = {https://www.ccjm.org/content/57/8/692}, eprint = {https://www.ccjm.org/content/57/8/692.full.pdf}, journal = {Cleveland Clinic Journal of Medicine} }